CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. FIFTH AMENDMENT TO...Commercialization Agreement • March 28th, 2014 • Ambrx Inc • Pharmaceutical preparations
This FIFTH AMENDMENT TO COLLABORATIVE RESEARCH, LICENSE & COMMERCIALIZATION AGREEMENT (the “Fifth Amendment”) is effective from 15-December-2010 by and between:
SECOND AMENDMENT TO LEASELease • March 28th, 2014 • Ambrx Inc • Pharmaceutical preparations
THIS SECOND AMENDMENT TO LEASE (this “Second Amendment”) is made as of December 1, 2011, by and between ARE-10933 NORTH TORREY PINES, LLC, a Delaware limited liability company (“Landlord”), and AMBRX, INC., a Delaware corporation (“Tenant”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 28th, 2014 • Ambrx Inc • Pharmaceutical preparations • California
This Executive Employment Agreement (“Agreement”) is made effective as Jan 6, 2013 (“Effective Date”), by and between Ambrx, Inc., a Delaware corporation (the “Company”), and Lawson Macartney (“Executive”).
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. COLLABORATIVE RESEARCH,...Commercialization Agreement • March 28th, 2014 • Ambrx Inc • Pharmaceutical preparations • New York
This COLLABORATIVE RESEARCH, LICENSE & COMMERCIALIZATION AGREEMENT (this “Agreement”) is effective from January 18, 2007 (the “Effective Date”) by and between:
AMENDMENT TO SEVERANCE AND CHANGE IN CONTROL AGREEMENTAnd Change in Control Agreement • March 28th, 2014 • Ambrx Inc • Pharmaceutical preparations
This Amendment (this “Amendment”) to Severance and Change in Control Agreement is made effective as of December 22, 2008. This Amendment amends the Severance and Change in Control Agreement, dated effective as of July 3, 2007, by and between Ambrx, Inc., a Delaware corporation (the “Company”) and Cris Calsada (“Executive”) (the “Agreement”).
FIRST AMENDMENT TO LEASE AGREEMENTLease Agreement • March 28th, 2014 • Ambrx Inc • Pharmaceutical preparations
THIS FIRST AMENDMENT TO LEASE AGREEMENT (this “First Amendment”) is made as of May 19, 2005, by and between ARE-10933 NORTH TORREY PINES, LLC, a Delaware limited liability company (“Landlord”), and AMBRX, INC., a Delaware corporation (“Tenant”).
COLLABORATION AND LICENSE AGREEMENT (FGF21)Collaboration and License Agreement • March 28th, 2014 • Ambrx Inc • Pharmaceutical preparations • New York
THIS COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is made and entered into effective as of September 21, 2011 (the “Effective Date”) by and between AMBRX, INC., a Delaware corporation having its principal place of business at 10975 North Torrey Pines Road, La Jolla, CA 92037 (“Ambrx”) and BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”). Ambrx and BMS are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 28th, 2014 • Ambrx Inc • Pharmaceutical preparations
This Amendment (this “Amendment” to Executive Employment Agreement is made effective as of December 22, 2008. This Amendment amends the Executive Employment Agreement, dated effective as of February 1, 2004, by and between Ambrx, Inc., a Delaware corporation (the “Company”), and John W. Wallen, III (“Executive”) (the “Agreement”).
SEVERANCE AND CHANGE IN CONTROL AGREEMENTSeverance and Change in Control Agreement • March 28th, 2014 • Ambrx Inc • Pharmaceutical preparations • California
This Severance and Change in Control Agreement (“Agreement”) is made effective as of July 3, 2007 (“Effective Date”), by and between Ambrx, Inc., a Delaware corporation (the “Company”), and Cris Calsada (“Executive”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 28th, 2014 • Ambrx Inc • Pharmaceutical preparations • California
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT No. 1 TO THE...License Agreement • March 28th, 2014 • Ambrx Inc • Pharmaceutical preparations
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT NO. 4 TO THE...Commercialization Agreement • March 28th, 2014 • Ambrx Inc • Pharmaceutical preparations • Indiana
THIS AMENDMENT NO. 4 to the Collaborative Research, License & Commercialization Agreement (“Amendment No. 4”), effective as of February 9, 2010 (“Effective Date”) is by and between Eli Lilly and Company, operating through its Elanco Animal Health division, 2001 W. Main Street, Greenfield, Indiana 46140 (“Elanco”) and Ambrx, Inc., 10975 North Torrey Pines Road, La Jolla, CA 92037 (“Ambrx”) (Elanco, together with Ambrx, the “Parties”).
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT NO. 2 TO...Agreement • March 28th, 2014 • Ambrx Inc • Pharmaceutical preparations
ELI LILLY AND COMPANY, an Indiana corporation operation through its Elanco Animal Health division and having a principal place of business at 2001 W. Main Street, Greenfield, Indiana 46140 (“Elanco”).
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. LICENSE AGREEMENT by and...License Agreement • March 28th, 2014 • Ambrx Inc • Pharmaceutical preparations • California
This License Agreement is entered into and made effective as of this 26th day of August, 2003 (the “Effective Date”), by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation (“TSRI”) located at 10550 North Torrey Pines Road, La Jolla, California 92037, and Ambrx, Inc., a Delaware corporation (“Licensee”) located at 10410 Science Center Drive, San Diego, California 92121, with respect to the facts set forth below.
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT NO. 1 TO...Agreement • March 28th, 2014 • Ambrx Inc • Pharmaceutical preparations
ELI LILLY AND COMPANY, an Indiana corporation operation through its Elanco Animal Health division and having a principal place of business at 2001 W. Main Street, Greenfield, Indiana 46140 (“Elanco”).
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT NO. 3 TO THE...Agreement • March 28th, 2014 • Ambrx Inc • Pharmaceutical preparations • Indiana
THIS AMENDMENT NO. 3 to the Collaborative Research, License & Commercialization Agreement (“Amendment No. 3”), effective as of December 21, 2009 (“Effective Date”) is by and between Eli Lilly and Company, operating through its Elanco Animal Health division, 2001 W. Main Street, Greenfield, Indiana 46140 (“Elanco”) and Ambrx, Inc., 10975 North Torrey Pines Road, La Jolla, CA 92037 (“Ambrx”) (Elanco, together with Ambrx, the “Parties”).
AMBRX, INC. AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 28th, 2014 • Ambrx Inc • Pharmaceutical preparations • California
This Amended and Restated Registration Rights Agreement (this “Agreement”) is made and entered into as of March 17, 2009 (the “Effective Date”) by and among Ambrx, Inc., a Delaware corporation (the “Company”) and the persons and entities set forth on Schedule A attached hereto (the “Investors”).
